A Study Of A New Medicine (GW597599B) For The Treatment Of Major Depressive Disorder

An 8-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Fixed-Dose Study Comparing the Efficacy and Safety of GW597599B or Paroxetine to Placebo in Moderately to Severely Depressed Patients With Major Depressive Disorder

A Placebo Controlled Study Evaluating Efficacy And Safety of Medication In Patients With Major Depressive Disorder (MDD)

Inclusion Criteria:

• Patients meet the diagnosis of Major Depressive Disorder (MDD).

Exclusion Criteria:

• Patients with a primary diagnosis other than MDD.
• Patients with a history of schizophrenia, schizoaffective disorders, seizure disorders or bipolar affective disorder.
• Patients receiving formal psychotherapy or cognitive/behavioral therapy concurrently or in the 12 weeks prior to screening visit.
• Patient is actively suicidal.
• Patients who have a history of migraine headaches.